Compare AMRX & GPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | GPI |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2018 | 1997 |
| Metric | AMRX | GPI |
|---|---|---|
| Price | $12.78 | $351.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $15.60 | ★ $444.50 |
| AVG Volume (30 Days) | ★ 1.4M | 95.1K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ 157.89 | N/A |
| EPS | 0.22 | ★ 25.24 |
| Revenue | N/A | ★ $11,123,721,000.00 |
| Revenue This Year | $4.48 | $3.41 |
| Revenue Next Year | $7.13 | $3.10 |
| P/E Ratio | $57.57 | ★ $13.62 |
| Revenue Growth | N/A | ★ 2.17 |
| 52 Week Low | $7.02 | $292.44 |
| 52 Week High | $15.42 | $488.39 |
| Indicator | AMRX | GPI |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 62.97 |
| Support Level | $12.50 | $325.19 |
| Resistance Level | $12.85 | $350.94 |
| Average True Range (ATR) | 0.49 | 10.68 |
| MACD | -0.01 | 0.65 |
| Stochastic Oscillator | 30.56 | 57.83 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Group 1 owns and operates 32 collision centers and 254 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 109 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.